Kiniksa (KNSA) COO 10b5-1 Sale and Option Exercise Reduces Holdings

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals insider transactions by COO Eben Tessari show a mix of purchases and sales executed under a 10b5-1 plan. The reporting person exercised 6,500 vested options at an exercise price of $8.83 on 08/18/2025, acquiring 6,500 Class A ordinary shares. On the same date the reporting person sold 16,100 shares at a weighted-average price of $33.77 and an additional 100 shares at $34.44, reducing beneficial ownership to 40,215 shares. The Form 4 notes the trades were effected pursuant to a 10b5-1 plan executed April 29, 2024, and the option is fully vested and exercisable through 09/16/2029.

Positive

• Exercise of 6,500 vested options at $8.83 indicates the reporting person converted lower-cost compensation into stock
• Transactions executed under a 10b5-1 plan, providing prearranged, documented trading that reduces concerns about opportunistic timing

Negative

• Sale of 16,200 shares (16,100 at weighted-average $33.77 and 100 at $34.44) materially reduced beneficial ownership to 40,215 shares
• Significant disposition size by an executive could be viewed negatively by some investors absent further context on remaining stake or reasons for sale

Insights

Financial Analyst

TL;DR: Insider exercised options cheaply and sold a larger block at much higher market prices under a 10b5-1 plan; results are routine but notable for size.

The reporting person exercised 6,500 options at $8.83 and sold 16,200 shares at a weighted-average above $33.7, locking in substantial gross proceeds relative to exercise cost. Because the transactions were made under a documented 10b5-1 plan, timing appears pre-arranged, reducing concerns about opportunistic trading on material nonpublic information. The net effect lowered beneficial ownership to 40,215 shares, which is meaningful for an executive-level holder but not dispositive without position size or % of outstanding shares.

Corporate Governance Expert

TL;DR: Transactions comply with 10b5-1 disclosure; the mix of exercise plus sales is governance-normal but merits tracking.

The Form 4 discloses use of a 10b5-1 plan executed April 29, 2024, which provides an affirmative defense for trading plans. The filing clearly states the option is fully vested and the sales were executed through a broker-dealer with a disclosed weighted-average sale price. From a governance perspective, documentation and transparent pricing disclosures are appropriate; no governance violations or unexplained exceptions appear in the filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tessari Eben

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	08/18/2025		M(1)		6,500	A	$8.83	56,415	D
Class A Ordinary Share	08/18/2025		S(1)		16,100	D	$33.77(2)	40,315	D
Class A Ordinary Share	08/18/2025		S(1)		100	D	$34.44	40,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$8.83	08/18/2025		M(1)			6,500	(3)	09/16/2029	Class A Ordinary Share	6,500	$0	25,500	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.41 and $34.405. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

3. The option is fully vested and exercisable.

	/s/ Aaron Young, Attorney-in-Fact	08/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did KNSA COO Eben Tessari report on Form 4?

The filing reports Tessari exercised 6,500 options at $8.83 and sold 16,100 shares at a weighted-average $33.77 plus 100 shares at $34.44 on 08/18/2025.

Were the trades executed under a 10b5-1 trading plan for KNSA?

Yes. The Form 4 states the transactions were effected pursuant to a 10b5-1 plan executed April 29, 2024.

How many KNSA shares does Tessari beneficially own after these transactions?

Following the reported transactions, the Form 4 shows Tessari beneficially owned 40,215 Class A ordinary shares.

Are the exercised options still exercisable and what are their terms?

The Form 4 indicates the option exercised is fully vested and exercisable, with exercisable/expiration information showing exercisable beginning 08/18/2025 and an expiration date of 09/16/2029.

What price range did the reported sales occur at?

The filing discloses the sales were executed at prices ranging from $33.41 to $34.405, with the weighted-average reported as $33.77.